Antibodies against TIM3 and uses thereof

US12312403B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Xiao Min Schebye · Palomar Park, US
• Mark J. Selby · San Francisco, US
• Michelle Minhua HAN · Piedmont, US
• Christine Bee · San Francisco, US
• Andy X. Deng · Princeton, US
• Anan Chuntharapai · Daly City, US
• Brigitte Devaux · Palo Alto, US
• Huiming LI · Lexington, US
• Paul O. Sheppard · Granite Falls, US
• Alan J. Korman · Piedmont, US
• Daniel F. ARDOUREL · Woodinville, US
• Ekaterina Deyanova · Lawrenceville, US
• Richard Y. Huang · Princeton, US
• Guodong Chen · East Brunswick Township, US
• Michelle Kuhne · San Francisco, US
• Hong-An TRUONG · San Francisco, US

Key dates

• Filing date: Feb 27, 2023
• Grant date: May 27, 2025
• Expiry date: Feb 27, 2043

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are antibodies, or antigen-binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen-binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen-binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen-binding portions thereof.